# DESCRIPTION

## FIELD OF THE INVENTION

- define conjugates for delivering therapeutics

## BACKGROUND OF THE INVENTION

- motivate neurotrophins
- summarize neurotrophins' ability
- limitations of BDNF
- describe TrkB agonist antibodies
- introduce VNARs

## SUMMARY OF THE INVENTION

- define conjugate
- describe BBB-shuttling VNAR domain
- application of conjugate
- embodiments of conjugate
- pharmaceutical compositions

## DETAILED DESCRIPTION OF THE INVENTION

- define key terms
- clarify word meanings
- explain grammatical variations
- define treatment and prevention
- describe effective amounts and perfusates
- define VNAR domains and structures
- explain binding and specific binding

### Conjugates of the Invention

- introduce conjugates of BBB-shuttling VNAR domains and neurotrophic agonist antibodies
- define BBB-shuttling VNAR domains
- describe TfR-binding VNAR domains
- provide examples of TfR-binding VNAR domains
- describe CD98-binding VNAR domains
- define neurotrophic agonist antibodies
- provide examples of neurotrophic agonist antibodies
- describe operable linkage of VNAR domains and neurotrophic agonist antibodies
- provide examples of conjugate arrangements
- describe associated diagnostic or therapeutic molecules
- provide examples of biologically active molecules
- describe imaging agents
- provide examples of imaging agents
- describe nucleic acid sequences that encode conjugates of the invention
- define isolated nucleic acid molecules
- describe fragments and derivatives of nucleic acid molecules
- provide examples of oligonucleotides
- describe derivatives or analogs of nucleic acid molecules
- define stringent hybridization conditions

### Methods of Producing Conjugates of the Invention

- outline production methods
- describe recombinant techniques
- detail vector components
- specify host cells
- describe purification procedures

### Methods of Treatment Using Conjugates of the Invention

- outline treatment methods
- specify diseases and conditions

### Pharmaceutical Compositions, Administration and Dosing

- define pharmaceutical compositions
- describe conjugates of the invention
- introduce pharmaceutically acceptable carriers
- discuss therapeutically effective amount
- describe factors affecting dosage
- introduce treatment and prophylactic measures
- define treatment
- describe unit dosage form
- introduce pharmaceutically acceptable antioxidants
- describe aqueous and nonaqueous carriers
- discuss adjuvants
- introduce isotonic agents
- describe absorption delaying agents
- discuss supplementary active compounds
- describe sterile and stable compositions
- introduce solution, microemulsion, and liposome formulations
- discuss coating and surfactant use
- describe isotonic and pH adjustment agents
- introduce sterile injectable solutions and powders
- describe parenterally acceptable protein solutions
- discuss dosage unit forms
- introduce dosage regimens
- describe administration routes and frequencies
- discuss sustained release formulations

### Kits and Delivery Devices

- introduce kits comprising conjugates and instructions
- describe devices for delivering conjugates

## EXAMPLES

- present examples of the invention

### Example 1. Construction and Purification of TfR-binding VNAR Conjugates with TrkB-AAbs

- construct TrkB-AAb conjugates with TXB4 VNAR
- purify and characterize the conjugates

### Example 2. VNAR-Mediated In Vivo Transport of TXB4-TrkB-AAb Conjugates Across the Blood Brain Barrier

- evaluate pharmacokinetics of TXB4-TrkB-AAb in plasma and brain
- assess brain uptake of conjugates using ELISA
- analyze binding of conjugates to TfR1

### Example 3. TrkB Agonist Activity of the TXB4-TrkB-AAb Conjugates

- measure activity of unconjugated TrkB antibody and conjugates
- compare activity to BDNF as positive control

### Example 4. TXB4-TrkB-AAb Conjugate Activity in a Parkinson's Disease Model

- describe 6-OHDA unilateral lesion model of Parkinson's disease
- administer TrkB(HV2N) conjugate to mice with 6-OHDA lesions
- evaluate neuroprotective potential of TrkB(HV2N) conjugate
- perform immunohistochemical assessment of TH+ cell bodies in SNc
- analyze TH+ nerve fibers in striatum
- count viable TH-positive A9 dopaminergic cells in SNc
- determine TH intensity in lesioned hemisphere
- compare results to PBS control group

